Dow Jones

38,834.86

0.15%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

CVTX

CV Therapeutics (CVTX)

CV Therapeutics (MM)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CVTX

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/04/2009	16:01	Edgar (US Regulatory)	Termination of Registration of a Class of Security under Section 12(g) (15-12G)	NASDAQ:CVTX	CV Therapeutics (MM)
17/04/2009	15:32	Edgar (US Regulatory)	(25-NSE)	NASDAQ:CVTX	CV Therapeutics (MM)
17/04/2009	15:15	Business Wire	Gilead Sciences Completes Acquisition of CV Therapeutics	NASDAQ:CVTX	CV Therapeutics (MM)
17/04/2009	12:29	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CVTX	CV Therapeutics (MM)
15/04/2009	14:54	Edgar (US Regulatory)	Amended Statement of Ownership: Solicitation (SC 14D9/A)	NASDAQ:CVTX	CV Therapeutics (MM)
14/04/2009	05:06	Edgar (US Regulatory)	Amended tender offer statement by Third Party (SC TO-T/A)	NASDAQ:CVTX	CV Therapeutics (MM)
09/04/2009	15:53	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:CVTX	CV Therapeutics (MM)
09/04/2009	14:11	Edgar (US Regulatory)	Schedule 13G	NASDAQ:CVTX	CV Therapeutics (MM)
08/04/2009	09:49	Marketwired	AnalystChoice.com Free Investment Opinion on PPDI, MEDX, CVTX and OSIP	NASDAQ:CVTX	CV Therapeutics (MM)
06/04/2009	15:12	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:CVTX	CV Therapeutics (MM)
18/03/2009	16:05	Marketwired	CV Therapeutics' Board of Directors Recommends Stockholders Accept Gilead Sciences' $20.00 per Share Cash Tender Offer	NASDAQ:CVTX	CV Therapeutics (MM)
18/03/2009	15:44	Edgar (US Regulatory)	Statement of Ownership: Solicitation (SC 14D9)	NASDAQ:CVTX	CV Therapeutics (MM)
18/03/2009	15:42	Edgar (US Regulatory)	Tender offer statement by Third Party (SC TO-T)	NASDAQ:CVTX	CV Therapeutics (MM)
18/03/2009	12:53	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:CVTX	CV Therapeutics (MM)
18/03/2009	12:52	Edgar (US Regulatory)	Written communication relating to an issuer or third party (SC TO-C)	NASDAQ:CVTX	CV Therapeutics (MM)
17/03/2009	08:07	Marketwired	Run of 100% Profitable Stock Alerts Marches on for BullTrade	NASDAQ:CVTX	CV Therapeutics (MM)
16/03/2009	16:13	Edgar (US Regulatory)	Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A)	NASDAQ:CVTX	CV Therapeutics (MM)
16/03/2009	15:57	Dow Jones News	MARKET SNAPSHOT: Corporate Cash Reserves, Cheap Stocks Could Trigger More M&A	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	15:01	Marketwired	CV Therapeutics Announces Presentations at the American College of Cardiology 58th Annual Scientific Session	NASDAQ:CVTX	CV Therapeutics (MM)
16/03/2009	14:01	Dow Jones News	UPDATE: US Drug Sector Rises After Bernanke Comments	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	13:49	Dow Jones News	MARKET SNAPSHOT: Corporate Cash Warchests, Cheap Stocks Could Trigger More M&A	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	10:10	Dow Jones News	Drug Sector Rises As Fed Chief Bernanke's Upbeat On Recession	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	04:12	Dow Jones News	UPDATE:Astellas Pharma Abandons Offer To Buy CV Therapeutics	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	02:08	Dow Jones News	Astellas Pharma: Withdrawing Offer To Buy CV Therapeutics	NASDAQ:CVTX	CV Therapeutics Inc.
16/03/2009	01:42	Business Wire	Astellas to Terminate Offer for CV Therapeutics	NASDAQ:CVTX	CV Therapeutics (MM)
13/03/2009	07:45	Dow Jones News	Genentech-Roche Deal Shows Attraction Of Biotech Assets	NASDAQ:CVTX	CV Therapeutics Inc.
12/03/2009	16:03	Edgar (US Regulatory)	Written communication by the subject company relating to a third party tender offer (SC14D9C)	NASDAQ:CVTX	CV Therapeutics (MM)
12/03/2009	13:15	PR Newswire (US)	CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer	NASDAQ:CVTX	CV Therapeutics (MM)
12/03/2009	09:06	Dow Jones News	UPDATE: Gilead To Buy CV Therapeutics For $1.4 Billion	NASDAQ:CVTX	CV Therapeutics Inc.
12/03/2009	08:22	Dow Jones News	Gilead To Buy CV Therapeutics For $1.4 Billion In White-Knight Bid	NASDAQ:CVTX	CV Therapeutics Inc.